The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life ...

Demonstrates Superior Sensitivity and Specificity of Caris DetectResults demonstrate the superiority of Whole Genome Sequencing compared to ...

We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of ...

Joining the call from Caris today are David Dean Halbert, our Founder, Chairman and CEO; David Spetzler, our President; Brian Brille, our Vice Chairman and EVP; Bobby Hill, our Chief Commercial ...

The human lymphatic system is notoriously difficult to map due to its size and variability among individuals. Spatial ...

Bioinformatics Market Size & Growth Analysis: "According to SNS Insider, The Bioinformatics Market size is estimated at USD 23.05 billion in 2025 and is expected to reach USD 91.95 billion by 2035, ...

An international research team has generated the first haplotype-resolved genome assemblies of Munage, one of China’s oldest ...

Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and nly simultaneous ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

HONG KONG, Feb. 13, 2026 /PRNewswire/ -- Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ ...